Salveen Richter
Stock Analyst at Goldman Sachs
(3.38)
# 1,376
Out of 4,479 analysts
133
Total ratings
42.71%
Success rate
3.96%
Average return
Main Sectors:
43 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Upgrades: Buy | $56 → $67 | $41.12 | +62.94% | 2 | Jun 6, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Neutral | $33 → $53 | $43.38 | +22.18% | 7 | Jun 4, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $28 → $19 | $11.03 | +72.26% | 6 | Apr 26, 2024 | |
| QURE uniQure | Downgrades: Neutral | $63 → $8 | $4.45 | +79.98% | 4 | Feb 29, 2024 | |
| DNLI Denali Therapeutics | Maintains: Buy | $73 → $50 | $22.01 | +127.17% | 4 | Feb 29, 2024 | |
| NTLA Intellia Therapeutics | Downgrades: Neutral | $32 | $22.47 | +42.41% | 5 | Feb 23, 2024 | |
| ADPT Adaptive Biotechnologies | Maintains: Neutral | $11 → $5 | $3.60 | +38.89% | 3 | Feb 16, 2024 | |
| ALNY Alnylam Pharmaceuticals | Downgrades: Neutral | $230 → $173 | $243.32 | -28.90% | 3 | Feb 16, 2024 | |
| AMGN Amgen | Maintains: Buy | $313 → $350 | $311.01 | +12.54% | 3 | Feb 8, 2024 | |
| FDMT 4D Molecular Therapeutics | Reinstates: Buy | $81 | $21.34 | +279.57% | 3 | Feb 7, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $442 → $559 | $471.25 | +18.62% | 3 | Jan 31, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $65 → $90 | $36.29 | +148.00% | 2 | Jan 9, 2024 | |
| INCY Incyte | Maintains: Neutral | $98 → $65 | $60.87 | +6.78% | 4 | Nov 22, 2023 | |
| MRNA Moderna | Maintains: Buy | $269 → $231 | $115.95 | +99.22% | 5 | Nov 3, 2023 | |
| IONS Ionis Pharmaceuticals | Maintains: Sell | $25 → $28 | $47.11 | -40.56% | 2 | Nov 3, 2023 | |
| TSVT 2seventy bio | Downgrades: Neutral | $5 | $4.05 | +23.46% | 4 | Sep 13, 2023 | |
| CNTA Centessa Pharmaceuticals | Maintains: Neutral | $4.5 → $5 | $8.80 | -43.18% | 5 | Aug 15, 2023 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $188 → $215 | $156.75 | +37.16% | 3 | Jun 23, 2023 | |
| FOLD Amicus Therapeutics | Maintains: Neutral | $10 → $11 | $9.80 | +12.24% | 1 | Mar 2, 2023 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $35 → $31 | $2.33 | +1,230.47% | 6 | Mar 2, 2023 | |
| ADSK Autodesk | Maintains: Overweight | $257 → $225 | $245.83 | -8.47% | 1 | Feb 24, 2023 | |
| PRME Prime Medicine | Initiates: Neutral | $22 | $5.48 | +301.46% | 1 | Nov 14, 2022 | |
| LYEL Lyell Immunopharma | Downgrades: Neutral | n/a | $1.58 | - | 4 | Nov 11, 2022 | |
| DTIL Precision BioSciences | Maintains: Neutral | $60 → $30 | $9.89 | +203.34% | 5 | Nov 10, 2022 | |
| KRON Kronos Bio | Maintains: Buy | $25 → $14 | $1.12 | +1,150.00% | 3 | Nov 10, 2022 | |
| RXRX Recursion Pharmaceuticals | Maintains: Neutral | $8 → $9 | $7.46 | +20.64% | 6 | Nov 9, 2022 | |
| TSHA Taysha Gene Therapies | Downgrades: Neutral | $16 → $3 | $2.26 | +32.74% | 4 | Nov 9, 2022 | |
| ACAD ACADIA Pharmaceuticals | Downgrades: Sell | $15 → $12 | $16.04 | -25.19% | 7 | Nov 4, 2022 | |
| SANA Sana Biotechnology | Maintains: Neutral | $7 → $6 | $5.47 | +9.69% | 2 | Nov 3, 2022 | |
| BFH Bread Financial Holdings | Maintains: Neutral | $39 → $43 | $45.33 | -5.14% | 1 | Oct 28, 2022 | |
| BIIB Biogen | Upgrades: Buy | $370 | $231.77 | +59.64% | 2 | Oct 26, 2022 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $796 → $970 | $1,057.02 | -8.23% | 2 | Oct 3, 2022 | |
| BLUE bluebird bio | Maintains: Sell | $2 → $3 | $0.98 | +207.60% | 4 | Aug 19, 2022 | |
| RLAY Relay Therapeutics | Maintains: Buy | $49 → $42 | $6.40 | +556.25% | 1 | May 24, 2022 | |
| OMGA Omega Therapeutics | Maintains: Neutral | $7 → $4 | $2.25 | +77.78% | 2 | May 24, 2022 | |
| CRSP CRISPR Therapeutics AG | Maintains: Neutral | $52 → $46 | $53.95 | -14.74% | 2 | May 24, 2022 | |
| CLLS Cellectis | Maintains: Sell | $3 → $2 | $1.94 | +3.36% | 2 | May 24, 2022 | |
| ATRA Atara Biotherapeutics | Maintains: Sell | $5 → $4 | $8.36 | -52.15% | 1 | May 24, 2022 | |
| RCUS Arcus Biosciences | Maintains: Neutral | $48 → $28 | $15.30 | +83.01% | 2 | May 12, 2022 | |
| GILD Gilead Sciences | Initiates: Neutral | n/a | $68.64 | - | 1 | Dec 6, 2021 | |
| PASG Passage Bio | Upgrades: Buy | n/a | $0.89 | - | 3 | Mar 4, 2021 | |
| PCAR PACCAR | Maintains: Neutral | n/a | $101.84 | - | 1 | Mar 19, 2020 | |
| ARWR Arrowhead Pharmaceuticals | Initiates: Neutral | n/a | $26.05 | - | 1 | Mar 17, 2020 |
Ultragenyx Pharmaceutical
Jun 6, 2024
Upgrades: Buy
Price Target: $56 → $67
Current: $41.12
Upside: +62.94%
Agios Pharmaceuticals
Jun 4, 2024
Maintains: Neutral
Price Target: $33 → $53
Current: $43.38
Upside: +22.18%
Sage Therapeutics
Apr 26, 2024
Maintains: Neutral
Price Target: $28 → $19
Current: $11.03
Upside: +72.26%
uniQure
Feb 29, 2024
Downgrades: Neutral
Price Target: $63 → $8
Current: $4.45
Upside: +79.98%
Denali Therapeutics
Feb 29, 2024
Maintains: Buy
Price Target: $73 → $50
Current: $22.01
Upside: +127.17%
Intellia Therapeutics
Feb 23, 2024
Downgrades: Neutral
Price Target: $32
Current: $22.47
Upside: +42.41%
Adaptive Biotechnologies
Feb 16, 2024
Maintains: Neutral
Price Target: $11 → $5
Current: $3.60
Upside: +38.89%
Alnylam Pharmaceuticals
Feb 16, 2024
Downgrades: Neutral
Price Target: $230 → $173
Current: $243.32
Upside: -28.90%
Amgen
Feb 8, 2024
Maintains: Buy
Price Target: $313 → $350
Current: $311.01
Upside: +12.54%
4D Molecular Therapeutics
Feb 7, 2024
Reinstates: Buy
Price Target: $81
Current: $21.34
Upside: +279.57%
Vertex Pharmaceuticals
Jan 31, 2024
Maintains: Buy
Price Target: $442 → $559
Current: $471.25
Upside: +18.62%
Apellis Pharmaceuticals
Jan 9, 2024
Maintains: Buy
Price Target: $65 → $90
Current: $36.29
Upside: +148.00%
Incyte
Nov 22, 2023
Maintains: Neutral
Price Target: $98 → $65
Current: $60.87
Upside: +6.78%
Moderna
Nov 3, 2023
Maintains: Buy
Price Target: $269 → $231
Current: $115.95
Upside: +99.22%
Ionis Pharmaceuticals
Nov 3, 2023
Maintains: Sell
Price Target: $25 → $28
Current: $47.11
Upside: -40.56%
2seventy bio
Sep 13, 2023
Downgrades: Neutral
Price Target: $5
Current: $4.05
Upside: +23.46%
Centessa Pharmaceuticals
Aug 15, 2023
Maintains: Neutral
Price Target: $4.5 → $5
Current: $8.80
Upside: -43.18%
Sarepta Therapeutics
Jun 23, 2023
Maintains: Buy
Price Target: $188 → $215
Current: $156.75
Upside: +37.16%
Amicus Therapeutics
Mar 2, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $9.80
Upside: +12.24%
Allogene Therapeutics
Mar 2, 2023
Maintains: Buy
Price Target: $35 → $31
Current: $2.33
Upside: +1,230.47%
Autodesk
Feb 24, 2023
Maintains: Overweight
Price Target: $257 → $225
Current: $245.83
Upside: -8.47%
Prime Medicine
Nov 14, 2022
Initiates: Neutral
Price Target: $22
Current: $5.48
Upside: +301.46%
Lyell Immunopharma
Nov 11, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.58
Upside: -
Precision BioSciences
Nov 10, 2022
Maintains: Neutral
Price Target: $60 → $30
Current: $9.89
Upside: +203.34%
Kronos Bio
Nov 10, 2022
Maintains: Buy
Price Target: $25 → $14
Current: $1.12
Upside: +1,150.00%
Recursion Pharmaceuticals
Nov 9, 2022
Maintains: Neutral
Price Target: $8 → $9
Current: $7.46
Upside: +20.64%
Taysha Gene Therapies
Nov 9, 2022
Downgrades: Neutral
Price Target: $16 → $3
Current: $2.26
Upside: +32.74%
ACADIA Pharmaceuticals
Nov 4, 2022
Downgrades: Sell
Price Target: $15 → $12
Current: $16.04
Upside: -25.19%
Sana Biotechnology
Nov 3, 2022
Maintains: Neutral
Price Target: $7 → $6
Current: $5.47
Upside: +9.69%
Bread Financial Holdings
Oct 28, 2022
Maintains: Neutral
Price Target: $39 → $43
Current: $45.33
Upside: -5.14%
Biogen
Oct 26, 2022
Upgrades: Buy
Price Target: $370
Current: $231.77
Upside: +59.64%
Regeneron Pharmaceuticals
Oct 3, 2022
Maintains: Buy
Price Target: $796 → $970
Current: $1,057.02
Upside: -8.23%
bluebird bio
Aug 19, 2022
Maintains: Sell
Price Target: $2 → $3
Current: $0.98
Upside: +207.60%
Relay Therapeutics
May 24, 2022
Maintains: Buy
Price Target: $49 → $42
Current: $6.40
Upside: +556.25%
Omega Therapeutics
May 24, 2022
Maintains: Neutral
Price Target: $7 → $4
Current: $2.25
Upside: +77.78%
CRISPR Therapeutics AG
May 24, 2022
Maintains: Neutral
Price Target: $52 → $46
Current: $53.95
Upside: -14.74%
Cellectis
May 24, 2022
Maintains: Sell
Price Target: $3 → $2
Current: $1.94
Upside: +3.36%
Atara Biotherapeutics
May 24, 2022
Maintains: Sell
Price Target: $5 → $4
Current: $8.36
Upside: -52.15%
Arcus Biosciences
May 12, 2022
Maintains: Neutral
Price Target: $48 → $28
Current: $15.30
Upside: +83.01%
Gilead Sciences
Dec 6, 2021
Initiates: Neutral
Price Target: n/a
Current: $68.64
Upside: -
Passage Bio
Mar 4, 2021
Upgrades: Buy
Price Target: n/a
Current: $0.89
Upside: -
PACCAR
Mar 19, 2020
Maintains: Neutral
Price Target: n/a
Current: $101.84
Upside: -
Arrowhead Pharmaceuticals
Mar 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $26.05
Upside: -